Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2NET 1Gynecologic 1Endocrine 1

Conditions

Lymphoma 3Stomatitis 2Small Cell Lung Carcinoma 2Neoplasms 2Mucositis 2Mouth Neoplasms 2Lung Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Small Cell 2Brain Neoplasms 2Spinal Cord Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Colorectal Neoplasms 1Cholangiocarcinoma 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 5Etoposide 4Pemetrexed 3Carboplatin 3pembrolizumab 2belinostat 2RRx-001 2vosaroxin 1taxane 1sagopilone 1pomalidomide 1lurtotecan 1liposomal doxorubicin 1etoposide phosphate 1enzalutamide 1atezolizumab 1abiraterone 1Vinorelbine 1Rhenium 1Radiation 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1PT-100 dipeptide 1PM 01183 1Molecular Diagnostic Techniques 1Irinotecan 1Immunotherapy 1Gemcitabine 1GSK2879552 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Small Cell × RRx-001 × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT03699956 2024-03-26

REPLATINUM

EpicentRx, Inc.

Phase 3 Terminated
18 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡